High Throughput Screening (HTS) Global Market Report 2024

The high throughput screening market size has grown rapidly in recent years. It will grow from $20.66 billion in 2023 to $22.98 billion in 2024 at a compound annual growth rate (CAGR) of 11.2%. The growth observed during the historic period can be attributed to several factors, including the increasing adoption of high-throughput screening techniques, a rise in Research and Development (R&D) spending across various industries, the growing availability of funds for research purposes, an increase in healthcare spending globally, and a competitive market landscape driving innovation and development in the field.

The high throughput screening market size is expected to see strong growth in the next few years. It will grow to $33.1 billion in 2028 at a compound annual growth rate (CAGR) of 9.5%. The anticipated growth in the forecast period can be attributed to several key factors, including the expansion of the market size and growth rate, strategic initiatives undertaken by key industry players, a rising demand for disease monitoring and drug discovery solutions, the increasing prevalence of chronic diseases globally, and a growing emphasis on implementing ultra-high-throughput screening (UHTS) techniques. Major trends expected during this period include technological advancements in high-throughput screening methodologies and an increasing focus on the adoption of ultra-high-throughput screening (UHTS) techniques to enhance efficiency and throughput in various research and development processes.

The expansion in chronic illness prevalence is anticipated to drive the progression of the high-throughput screening (HTS) market in the future. Chronic diseases denote prolonged health conditions persisting over three months or more. HTS facilitates swift examination of numerous chemical compounds to identify potential drug candidates aimed at specific pathways or mechanisms linked to chronic ailments, crucial for their effective long-term control. For example, as per a report released by the National Library of Medicine in January 2023, the projected rise in individuals aged 50 and above with one or more chronic diseases in the United States is expected to soar by 99.5%, reaching 142.66 million by 2050, compared to 71.522 million in 2020.

Prominent enterprises operating within the high-throughput screening market are innovating their product lines to cater to their clientele with advanced functionalities. A multimode plate reader (MPR) represents an advanced laboratory apparatus employed in high-throughput screening, analyzing biological and chemical samples in microplates by integrating multiple detection modes for various assays within a unified platform. For instance, in February 2023, PerkinElmer Inc., a United States-based MedTech firm, unveiled the EnVision Nexus system. Positioned as the swiftest and most sensitive multimode plate reader in the market, the EnVision Nexus system is expressly crafted for demanding high-throughput screening (HTS) applications to accelerate drug discovery endeavors. Boasting distinctive technology, including dual detectors and optimized reagents such as proprietary HTRF and AlphaLISA, alongside cutting-edge reagent kits, the platform furnishes researchers with unmatched assay flexibility, precision, velocity, and sensitivity. Outfitted with user-friendly features such as a plate stacker for 20 or 50 plates and full automation and integration for uninterrupted 24/7 workflow-driven operations, the EnVision Nexus system empowers researchers to efficiently screen millions of samples with unprecedented efficiency.

In December 2023, PerkinElmer Inc., a prominent US-based MedTech firm, completed the acquisition of Covaris Inc. for an undisclosed sum. This strategic move is expected to expedite Covaris' growth trajectory, while simultaneously enabling PerkinElmer to broaden its footprint in the burgeoning diagnostics segment within the life sciences industry. Covaris Inc., renowned for its high-throughput screening solutions, brings valuable expertise and technology to complement PerkinElmer's existing portfolio.

Major companies operating in the high throughput screening (HTS) market report are Thermo Fisher Scientific Inc., AstraZeneca Plc, Danaher Corporation, Merck Group, GE HealthCare Technologies Inc., Corning Inc., Agilent Technologies Inc., Lonza Group Ltd., Charles River Laboratories International Inc, Beckman Coulter Inc., PerkinElmer Inc., Bio-Rad Laboratories, Tecan Group Ltd., Sygnature Discovery Ltd., Luminex Corporation, Hamilton Company, Crown Bioscience Inc., HighRes Biosolutions, NanoTemper Technologies GmbH, BMG LABTECH GmbH, Axxam SpA, Reprocell Inc., BioTek Instruments Inc, Aurora Biomed Inc., Cyclica Inc., Biomat Srl, Diana Biotechnologies s.r.o.

North America was the largest region in the high throughput screening market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the high throughput screening (HTS) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the high throughput screening (HTS) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

High-throughput screening (HTS) is a technique employed in drug discovery and various scientific domains to rapidly assess a large number of samples for biological activity. Its purpose is to identify active compounds, antibodies, or genes that modulate specific biological pathways, thereby expediting the drug discovery process.

The main types of products and services in high-throughput screening (HTS) are consumables and reagents, instruments, software, and services. Consumables and reagents refer to the materials and chemicals used in the screening process, including sample containers, assay reagents, and other disposable items necessary for experimental procedures. The technology types are categorized into ultra-high-throughput screening, cell-based assays, lab-on-a-chip, and label-free technology, which are used in several applications such as target identification and validation, primary and secondary screening, toxicology assessment, and others. The end users include the pharmaceutical and biotechnology industries, academic and research institutes, contract research organizations, and others.

The high throughput screening (HTS) research report is one of a series of new reports that provides high throughput screening (HTS) market statistics, including the high throughput screening (HTS) industry's global market size, regional shares, competitors with an High throughput screening (HTS) market share, detailed high throughput screening (HTS) market segments, market trends and opportunities, and any further data you may need to thrive in the high throughput screening (HTS) industry. This high throughput screening (HTS) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The high-throughput screening (HTS) market consists of revenues earned by entities by providing services such as compound library screening, assay design and adaptation, and pilot screening. The market value includes the value of related goods sold by the service provider or included within the service offering. The high-throughput screening (HTS) market also includes sales of lab equipment and supplies, chemicals, assay development tools, and data processing software. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.